A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved ... The data with the CRISPR/Cas9 drug CTX001 is still very early-stage, coming from just seven thalassaemia ...
Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can ... to begin an early stage trial of CTX001, a gene therapy derived from ...
CRISPR Therapeutics' stock is down 19% since December ... but $35M in collaboration revenue from Vertex and a net loss of $37.311M. Despite pioneering technology, CRISPR faces slow gene therapy ...
Furthermore, CRISPR Therapeutics will share the profits generated from Casgevy with Vertex Pharmaceuticals, with which it developed the medicine; Vertex is entitled to 60% of the program profits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback